Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec 20;40(36):4161-4165.
doi: 10.1200/JCO.22.01066. Epub 2022 Jul 21.

What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?

Ryan J Sullivan  1
Affiliations
Editorial

What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?

Ryan J Sullivan. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ryan J. Sullivan

Consulting or Advisory Role: Novartis, Merck, Replimune, Asana Biosciences, Alkermes, Eisai, Pfizer, Iovance Biotherapeutics, OncoSec, AstraZeneca, Bristol Myers Squibb

Research Funding: Amgen (Inst), Lilly (Inst), BioMed Valley Discoveries (Inst), Merck (Inst), Deciphera (Inst), Roche/Genentech (Inst), Moderna Therapeutics (Inst), Sanofi (Inst), Aeglea Biotherapeutics (Inst), Asana Biosciences (Inst), Viralytics (Inst), Compugen (Inst), Neon Therapeutics (Inst), Pfizer (Inst), BeiGene (Inst), Rubius Therapeutics (Inst), Strategia (Inst)

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
A timeline of US Food and Drug Administration approvals for the treatment of advanced (unresectable stage III or stage IV) melanoma. (A) Agents in red are either BRAF or MEK inhibitors and are only approved for patients with BRAFV600-mutant melanoma. (B) Agents in blue are immunotherapies. The long-term survival of frontline therapy for advanced melanoma is shown. COBI, cobimetinib; DAB/TRAM, dabrafenib plus trametinib; DTIC, dacarbazine; ENCO/BINI, encorafenib plus binimetinib; FDC, fixed dose combination; IL-2, interleukin 2; IPI, ipilimumab,; IPI/NIVO, combination of ipilimumab plus nivolumab; NIVO, nivolumab; PEMBRO, pembrolizumab; TVEC, talimogene laherparepvec; VEM, vemurafenib,; VEM/COBI, vemurafenib plus cobimetinib.
See this image and copyright information in PMC

Comment on

References

    1. Cancer Genome Atlas Network Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–1696. - PMC - PubMed
    1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516. - PMC - PubMed
    1. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–114. - PubMed
    1. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365. - PubMed
    1. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39. - PubMed

Substances